Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
43
TLSI Quote, Financials, Valuation and Earnings
Last price:
$7.06
Seasonality move
:
29.79%
Day range:
$6.99 - $7.28
52-week range:
$3.42 - $7.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.80x
P/B ratio:
--
Volume:
32.7K
Avg. volume:
211.2K
1-year change:
48.63%
Market cap:
$352.7M
Revenue:
$29.4M
EPS (TTM):
-$2.02
Analysts' Opinion
-
Consensus RatingTriSalus Life Sciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.50, TriSalus Life Sciences, Inc. has an estimated upside of 62.89% from its current price of $7.06.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing -27.48% downside risk from its current price of $7.06.
Fair Value
-
According to the consensus of 6 analysts, TriSalus Life Sciences, Inc. has 62.89% upside to fair value with a price target of $11.50 per share.
TLSI vs. S&P 500
-
Over the past 5 trading days, TriSalus Life Sciences, Inc. has underperformed the S&P 500 by -4.65% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
TriSalus Life Sciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
TriSalus Life Sciences, Inc. has grown year-over-year revenues for 11 quarters straight. In the most recent quarter TriSalus Life Sciences, Inc. reported revenues of $11.6M.
Earnings Growth
-
TriSalus Life Sciences, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter TriSalus Life Sciences, Inc. reported earnings per share of -$0.96.
Enterprise value:
364.2M
EV / Invested capital:
49.22x
Price / LTM sales:
5.80x
EV / EBIT:
--
EV / Revenue:
9.06x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-16.43x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$33.4M
Return On Assets:
-125.38%
Net Income Margin (TTM):
-98.45%
Return On Equity:
--
Return On Invested Capital:
-936.41%
Operating Margin:
-77.94%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $16M | $26.9M | $40.2M | $7.3M | $11.6M | |
| Gross Profit | $12.7M | $22.8M | $33.4M | $6.2M | $9.7M | |
| Operating Income | -$51.9M | -$42.8M | -$31.3M | -$8.7M | -$9M | |
| EBITDA | -$51.4M | -$41.8M | -$30.4M | -$8.5M | -$8.9M | |
| Diluted EPS | -$76.33 | -$2.50 | -$2.02 | -$0.12 | -$0.96 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $702.4K | $306.2K | $29M | $23.8M | $33.3M | |
| Total Assets | $250.8M | $251.3M | $33.6M | $27.5M | $36.5M | |
| Current Liabilities | $696.6K | $1.9M | $9.3M | $9.9M | $10.9M | |
| Total Liabilities | $20.4M | $12.2M | $25.1M | $47.9M | $63.2M | |
| Total Equity | $230.4M | $239.2M | $8.5M | -$20.4M | -$26.7M | |
| Total Debt | -- | $700K | $1.3M | $23.2M | $34M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$49.7M | -$44.3M | -$21.2M | -$10.8M | -$3.7M | |
| Cash From Investing | -$1.5M | -$667K | -$847K | -$169K | -$176K | |
| Cash From Financing | $60.5M | $35M | $33.5M | $5.8M | $82K | |
| Free Cash Flow | -$50.2M | -$45M | -$22.2M | -$11M | -$3.9M | |
TLSI
Sector
Market Cap
$352.7M
$28M
Price % of 52-Week High
88.81%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-11.37%
-1.54%
1-Year Price Total Return
48.63%
-17.48%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$7.29
200-day SMA
Buy
Level
$5.20
Bollinger Bands (100)
Buy
Level
4.16 - 6.2
Chaikin Money Flow
Buy
Level
668.8K
20-day SMA
Buy
Level
$7.05
Relative Strength Index (RSI14)
Buy
Level
59.40
ADX Line
Sell
Level
13.41
Williams %R
Neutral
Level
-66.171
50-day SMA
Buy
Level
$5.70
MACD (12, 26)
Buy
Level
1.90
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
1.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-17.6694)
Sell
CA Score
(Annual)
Level (-14.0043)
Sell
Beneish M-Score
(Annual)
Level (-1.0583)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (15.6304)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.
Stock Forecast FAQ
In the current month, TLSI has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TLSI average analyst price target in the past 3 months is $11.50.
-
Where Will TriSalus Life Sciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that TriSalus Life Sciences, Inc. share price will rise to $11.50 per share over the next 12 months.
-
What Do Analysts Say About TriSalus Life Sciences, Inc.?
Analysts are divided on their view about TriSalus Life Sciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that TriSalus Life Sciences, Inc. is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is TriSalus Life Sciences, Inc.'s Price Target?
The price target for TriSalus Life Sciences, Inc. over the next 1-year time period is forecast to be $11.50 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TLSI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for TriSalus Life Sciences, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TLSI?
You can purchase shares of TriSalus Life Sciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase TriSalus Life Sciences, Inc. shares.
-
What Is The TriSalus Life Sciences, Inc. Share Price Today?
TriSalus Life Sciences, Inc. was last trading at $7.06 per share. This represents the most recent stock quote for TriSalus Life Sciences, Inc.. Yesterday, TriSalus Life Sciences, Inc. closed at $7.06 per share.
-
How To Buy TriSalus Life Sciences, Inc. Stock Online?
In order to purchase TriSalus Life Sciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TLSI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TLSI
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
--
1.82x
Price / LTM sales
5.80x
1.60x
Growth Metrics
TLSI
Sector
Revenue growth
57.38%
4.62%
Earnings growth
-693.54%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.17
-$0.21
Profitability
TLSI
Sector
Profitability FY 2024
$24.6M
$3.5M
Return on invested capital
-936.41%
-31.77%
Return on assets
-125.38%
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
12
Balance Sheet
TLSI
Sector
Total cash
$22.7M
$26.3M
Short term investments
--
$25.7M
Total assets
$24M
$78M
Long term debt
$34M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
